IL129910A0 - Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis - Google Patents
Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosisInfo
- Publication number
- IL129910A0 IL129910A0 IL12991097A IL12991097A IL129910A0 IL 129910 A0 IL129910 A0 IL 129910A0 IL 12991097 A IL12991097 A IL 12991097A IL 12991097 A IL12991097 A IL 12991097A IL 129910 A0 IL129910 A0 IL 129910A0
- Authority
- IL
- Israel
- Prior art keywords
- low density
- methods
- density lipoprotein
- binding proteins
- treating atherosclerosis
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 4
- 102000007330 LDL Lipoproteins Human genes 0.000 title abstract 4
- 108010007622 LDL Lipoproteins Proteins 0.000 title abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 2
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3193096P | 1996-11-27 | 1996-11-27 | |
| US4854797P | 1997-06-03 | 1997-06-03 | |
| PCT/US1997/021857 WO1998023282A1 (en) | 1996-11-27 | 1997-11-26 | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL129910A0 true IL129910A0 (en) | 2000-02-29 |
Family
ID=26707786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12991097A IL129910A0 (en) | 1996-11-27 | 1997-11-26 | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6355451B1 (ja) |
| EP (1) | EP0969855B1 (ja) |
| JP (1) | JP4184437B2 (ja) |
| AT (1) | ATE317264T1 (ja) |
| AU (1) | AU736142B2 (ja) |
| CA (1) | CA2272243A1 (ja) |
| DE (1) | DE69735243T2 (ja) |
| ES (1) | ES2258798T3 (ja) |
| IL (1) | IL129910A0 (ja) |
| WO (1) | WO1998023282A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605588B1 (en) | 1996-11-27 | 2003-08-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| US6632923B1 (en) | 1996-11-27 | 2003-10-14 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| JP2004536082A (ja) * | 1999-10-22 | 2004-12-02 | グラクソ グループ リミテッド | ｉｎｖｉｖｏイメージング |
| CN1329142A (zh) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——rna聚合酶ii相关蛋白11.33和编码这种多肽的多核苷酸 |
| US20050154407A1 (en) * | 2000-12-20 | 2005-07-14 | Fox Hollow Technologies, Inc. | Method of evaluating drug efficacy for treating atherosclerosis |
| US20060032508A1 (en) * | 2000-12-20 | 2006-02-16 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
| US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
| WO2009154025A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 酸化LDL/β2GPI複合体に対する抗体及びその用途 |
| IN2014DN09963A (ja) * | 2012-06-06 | 2015-08-14 | Inst Nat Sante Rech Med |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59206046A (ja) | 1983-05-11 | 1984-11-21 | Asahi Chem Ind Co Ltd | 低比重リポ蛋白質を吸着する材料 |
| US4660563A (en) | 1984-12-31 | 1987-04-28 | Massachusetts Institute Of Technology | Method and means for detection of arterial lesions |
| US4877599A (en) | 1986-11-10 | 1989-10-31 | New England Deaconess Hospital Corporation | Detection of vascular disease with labelled antibodies |
| US5726153A (en) | 1988-05-02 | 1998-03-10 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| US5135848A (en) | 1989-10-23 | 1992-08-04 | Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa | Methods for evaluating cholesterol metabolism and reagents therefor |
| US5196324A (en) | 1989-12-15 | 1993-03-23 | Eli Lilly And Company | Monoclonal antibodies reactive with a human atheroma associated antigen |
| AU663291B2 (en) | 1990-05-03 | 1995-10-05 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| DE4222385A1 (de) | 1992-07-08 | 1994-01-13 | Boehringer Ingelheim Int | Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors |
| EP0586094A1 (en) | 1992-08-03 | 1994-03-09 | Wisconsin Alumni Research Foundation | Soluble LDL receptor and gene |
| AU6234194A (en) | 1993-01-15 | 1994-08-15 | Board Of Regents, The University Of Texas System | High molecular weight b-cell growth factor: interleukin-14 |
| JPH09163988A (ja) | 1995-10-09 | 1997-06-24 | Kowa Co | 新規なｌｄｌ受容体類似蛋白質及び遺伝子 |
-
1997
- 1997-11-26 AU AU74088/98A patent/AU736142B2/en not_active Ceased
- 1997-11-26 US US08/979,608 patent/US6355451B1/en not_active Expired - Fee Related
- 1997-11-26 EP EP97949680A patent/EP0969855B1/en not_active Expired - Lifetime
- 1997-11-26 AT AT97949680T patent/ATE317264T1/de not_active IP Right Cessation
- 1997-11-26 IL IL12991097A patent/IL129910A0/xx unknown
- 1997-11-26 CA CA002272243A patent/CA2272243A1/en not_active Abandoned
- 1997-11-26 WO PCT/US1997/021857 patent/WO1998023282A1/en active IP Right Grant
- 1997-11-26 ES ES97949680T patent/ES2258798T3/es not_active Expired - Lifetime
- 1997-11-26 JP JP52487098A patent/JP4184437B2/ja not_active Expired - Fee Related
- 1997-11-26 DE DE69735243T patent/DE69735243T2/de not_active Expired - Lifetime
-
2001
- 2001-09-24 US US09/962,055 patent/US20020052033A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0969855A1 (en) | 2000-01-12 |
| JP2001506983A (ja) | 2001-05-29 |
| ES2258798T3 (es) | 2006-09-01 |
| WO1998023282A1 (en) | 1998-06-04 |
| US6355451B1 (en) | 2002-03-12 |
| EP0969855B1 (en) | 2006-02-08 |
| AU736142B2 (en) | 2001-07-26 |
| CA2272243A1 (en) | 1998-06-04 |
| ATE317264T1 (de) | 2006-02-15 |
| AU7408898A (en) | 1998-06-22 |
| JP4184437B2 (ja) | 2008-11-19 |
| DE69735243D1 (de) | 2006-04-20 |
| DE69735243T2 (de) | 2006-11-02 |
| US20020052033A1 (en) | 2002-05-02 |
| EP0969855A4 (en) | 2001-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lorenzo et al. | Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis | |
| Skerrow et al. | Chemical characterization of isolated epidermal desmosomes | |
| AU2001243322A1 (en) | Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
| AR006188A1 (es) | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". | |
| BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
| NZ332634A (en) | Isolated autophosphorylating polypeptide having phosphoinositide-3-kinase activity | |
| ATE352559T1 (de) | Verfahren zur verminderung der immunogenität von proteinen | |
| BR9712518A (pt) | Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico | |
| Julien et al. | A Comparison of In Vitro‐and In Vivo Phosphorylated Neurofilament Polypeptides | |
| Appelbaum et al. | In vivo phosphorylation of the lamin B receptor. Binding of lamin B to its nuclear membrane receptor is affected by phosphorylation. | |
| IL129910A0 (en) | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
| TR199802082T2 (xx) | Otoantigen ve otoim�n hastal�klar�n im�noterapisinde kullan�lmak i�in otoantigen yap�sal olarak ili�kili proteinler. | |
| EP1270585A4 (en) | PEPTIDE DERIVATIVE | |
| BR9506377A (pt) | Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas | |
| ES2173471T3 (es) | Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos. | |
| BR0010563A (pt) | Composições isoladas de células da pele e métodos para seu uso | |
| DE68925275D1 (de) | Endotoxin-bindeprotein und dessen verwendung | |
| DK525384D0 (da) | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat | |
| BG103872A (en) | Glycoconjugates of 20(s)-camptotecin | |
| NO972063L (no) | Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle | |
| EA199800352A1 (ru) | ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА | |
| Kleftogiannis et al. | Characterization of extracellular matrix macromolecules from bovine synovial capsule | |
| EP0300487A3 (en) | Enzymatically inactive, immunologically active beta-galactosidase muteins | |
| EP2301947A3 (en) | Secreted proteins and uses thereof | |
| Scott et al. | Production of fibrolast-pneumocyte-like factor by fetal rabbit lung fibroblasts: Isolation and effects of it and related factors on fetal type II cells in vitro |